Compare BIO-TECHNE Corp (TECH) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard International High Dividend Yield ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Vanguard International High Dividend Yield ETF trades at $104.45. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals.
| TECH | VYMI | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $72.29 | $105.05 |
52-Week Low | $43.31 | $82.61 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VYMI trades at $105.05, up 0.64% on the day, near its 52-week high with a bullish technical signal. The ETF offers a 3.4% dividend yield and has delivered strong returns, outperforming the S&P 500 with a 55% total return since last coverage. Recent institutional buying and positive media coverage highlight growing investor interest in its international high-dividend strategy.
Outlook remains positive due to diversification benefits and dividend growth, but risks include currency fluctuations and global economic volatility. Analysts favor its yield and growth potential, though overbought RSI levels suggest near-term consolidation may occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
